In EDS ansehen

Differences in Sentinel lymph node biopsy outcomes and prognosis between HER2-low and HER2-zero breast cancer

Gespeichert in:
Bibliographische Detailangaben
Titel: Differences in Sentinel lymph node biopsy outcomes and prognosis between HER2-low and HER2-zero breast cancer
Autoren: Koji Takada, Shinichiro Kashiwagi, Mariko Nishikawa, Asuka Kochi, Chika Watanabe, Haruhito Kinoshita, Kana Ogisawa, Masatsune Shibutani, Tamami Morisaki
Quelle: BMC Cancer, Vol 25, Iss 1, Pp 1-11 (2025)
Verlagsinformationen: BMC, 2025.
Publikationsjahr: 2025
Bestand: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Schlagwörter: Breast cancer, HER2-low, Prognosis, Sentinel lymph node, Axillary lymph node dissection, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Beschreibung: Abstract Purpose Human epidermal growth factor receptor 2 (HER2)-low breast cancer has been recognized as a distinct biological subset within HER2-negative breast cancer. This study aimed to examine the differences in sentinel lymph node metastasis (SLNM) rates and prognosis between HER2-low and HER2-zero breast cancers. Methods This retrospective study evaluated 965 estrogen receptor-positive, HER2-negative breast cancer patients who underwent sentinel lymph node biopsy at Osaka Metropolitan University Hospital. Clinicopathological characteristics, SLNM rates, and prognostic outcomes were compared between patients with HER2-low and with HER2-zero breast cancers. Results The SLNM rate was significantly higher in the HER2-low group than in the HER2-zero group (p = 0.039). However, disease-free survival (DFS), recurrence-free interval (RFI), overall survival, and breast cancer-specific survival were not significantly different between the two groups. In subgroup analysis excluding macrometastases, DFS and RFI were significantly longer in the HER2-low breast cancer group. Conclusion HER2-low breast cancer exhibits a higher SLNM rate, suggesting unique biological behavior. However, its overall prognosis remains similar to that of HER2-zero breast cancer, with potential prognostic advantages in select subgroups.
Publikationsart: article
Dateibeschreibung: electronic resource
Sprache: English
ISSN: 1471-2407
Relation: https://doaj.org/toc/1471-2407
DOI: 10.1186/s12885-025-14970-8
Zugangs-URL: https://doaj.org/article/a54d7ad2e8d04a8c9f2327b7c755b313
Dokumentencode: edsdoj.54d7ad2e8d04a8c9f2327b7c755b313
Datenbank: Directory of Open Access Journals
Beschreibung
Abstract:Abstract Purpose Human epidermal growth factor receptor 2 (HER2)-low breast cancer has been recognized as a distinct biological subset within HER2-negative breast cancer. This study aimed to examine the differences in sentinel lymph node metastasis (SLNM) rates and prognosis between HER2-low and HER2-zero breast cancers. Methods This retrospective study evaluated 965 estrogen receptor-positive, HER2-negative breast cancer patients who underwent sentinel lymph node biopsy at Osaka Metropolitan University Hospital. Clinicopathological characteristics, SLNM rates, and prognostic outcomes were compared between patients with HER2-low and with HER2-zero breast cancers. Results The SLNM rate was significantly higher in the HER2-low group than in the HER2-zero group (p = 0.039). However, disease-free survival (DFS), recurrence-free interval (RFI), overall survival, and breast cancer-specific survival were not significantly different between the two groups. In subgroup analysis excluding macrometastases, DFS and RFI were significantly longer in the HER2-low breast cancer group. Conclusion HER2-low breast cancer exhibits a higher SLNM rate, suggesting unique biological behavior. However, its overall prognosis remains similar to that of HER2-zero breast cancer, with potential prognostic advantages in select subgroups.
ISSN:14712407
DOI:10.1186/s12885-025-14970-8